Original language | English |
---|---|
Pages (from-to) | s8 |
Journal | SKIN: Journal of Cutaneous Medicine |
Volume | 6 |
Issue number | 2 |
DOIs |
|
State | Published - 4 Mar 2022 |
Externally published | Yes |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: SKIN: Journal of Cutaneous Medicine, Vol. 6, No. 2, 04.03.2022, p. s8.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial
AU - Bagel, Jerry
AU - Gold, Linda Stein
AU - Rosso, James Del
AU - Bhatia, Neal
AU - Johnson, Sandy
AU - Yamauchi, Paul
AU - Moore, Angela Y.
AU - Tallman, Anna M.
N1 - Funding Information: Trials were funded by Dermavant Sciences, Inc. and the authors thank the investigators, patients and their families, and colleagues involved in their conduct. J.B. has received research funds payable to Psoriasis Treatment Center and/or speaking/consultant fees from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Corrona LLC, Dermavant Sciences, Ltd, Dermira / UCB, Eli Lilly, Glenmark Pharmaceuticals Ltd, Janssen Biotech, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro Pharmaceutical Industries Ltd, UCB, and Valeant Pharmaceuticals. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. J.D.R. is a consultant and research investigator for Dermavant Sciences, Inc. N.B. is a consultant with honorarium and an investigator for Dermavant Sciences, Inc. SJ is an advisor and/or speaker and/or editor and/or involved in clinical trials for AbbVie, Aclaris, AFMC, Allergan, Candela Syneron, Cassiopea, Celgene, Amgen, Chemocentryx, Dermavant Sciences, Inc., Dermira, Foamix, Gage, Galderma, GSK, Journal of Arkansas Medical Society, LEO, Eli Lilly, National Psoriasis Foundation, Nielsen, Novartis, Practical Dermatology, Regeneron, Sanofi Genzyme, Skin Medical, TARGET Therapeutics, and the University of Pennsylvania. P.Y. has served as an investigator and/or speaker and/or consultant for AbbVie, Amgen, Arcutis, BMS, Dermavant, EPI Health, Incyte, Janssen, Lilly, Leo, Novartis, Pfizer, Sun Pharma, and UCB. A.Y.M. has served as an investigator for Dermavant Sciences, Inc. A.M.T. is an employee of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Contact Dr Bagel at dreamacres1@ aol.com with questions or comments. Funding Information: Trials were funded by Dermavant Sciences, Inc. and the authors thank the investigators, patients and their families, and colleagues involved in their conduct. J.B. has received research funds payable to Psoriasis Treatment Center and/or speaking/consultant fees from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Corrona LLC, Dermavant Sciences, Ltd, Dermira/UCB, Eli Lilly, Glenmark Pharmaceuticals Ltd, Janssen Biotech, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro Pharmaceutical Industries Ltd, UCB, and Valeant Pharmaceuticals. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. J.D.R. is a consultant and research investigator for Dermavant Sciences, Inc. N.B. is a consultant with honorarium and an investigator for Dermavant Sciences, Inc. SJ is an advisor and/or speaker and/or editor and/or involved in clinical trials for AbbVie, Aclaris, AFMC, Allergan, Candela Syneron, Cassiopea, Celgene, Amgen, Chemocentryx, Dermavant Sciences, Inc., Dermira, Foamix, Gage, Galderma, GSK, Journal of Arkansas Medical Society, LEO, Eli Lilly, National Psoriasis Foundation, Nielsen, Novartis, Practical Dermatology, Regeneron, Sanofi Genzyme, Skin Medical, TARGET Therapeutics, and the University of Pennsylvania. P.Y. has served as an investigator and/or speaker and/or consultant for AbbVie, Amgen, Arcutis, BMS, Dermavant, EPI Health, Incyte, Janssen, Lilly, Leo, Novartis, Pfizer, Sun Pharma, and UCB. A.Y.M. has served as an investigator for Dermavant Sciences, Inc. A.M.T. is an employee of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Contact Dr Bagel at [email protected] with questions or comments.
PY - 2022/3/4
Y1 - 2022/3/4
UR - http://www.scopus.com/inward/record.url?scp=85136297519&partnerID=8YFLogxK
U2 - 10.25251/skin.6.supp.8
DO - 10.25251/skin.6.supp.8
M3 - Comment/debate
AN - SCOPUS:85136297519
SN - 2574-1624
VL - 6
SP - s8
JO - SKIN: Journal of Cutaneous Medicine
JF - SKIN: Journal of Cutaneous Medicine
IS - 2
ER -